Skip to main content

Table 2 Clinical outcomes at 24-month follow-up

From: Impact of glycemic control status on patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention

Adverse EventsGroup 1 (174)Group 2 (64)Group 3 (112)P value
overall1 vs 21 vs 32 vs 3
All-cause death2 (1.1%)5 (7.8%)21 (18.8%)< 0.0010.007< 0.0010.048
MACCEs6 (3.4%)7 (10.9%)28 (25%)< 0.0010.024< 0.0010.025
Cardiac death1 (0.6%)2 (3.1%)21 (18.8%)< 0.0010.116< 0.0010.004
Stent thrombosis2 (1.1%)0 (0)1 (0.9%)0.70.3900.8740.418
Repeat revascularization2 (1.1%)4 (6.3%)4 (3.6%)0.0850.0240.1110.532
MI2 (1.1%)0 (0)3 (2.7%)0.2640.4030.2680.170
Stroke0 (0)1 (1.6%)1 (0.9%)0.2960.1610.1610.776
  1. Values expressed are n (%). MACCEs major adverse cardiac and cerebrovascular event, includes cardiac death, stent thrombosis, repeat revascularization, MI and stroke, MI myocardial infarction